Turn Therapeutics Inc.

For the period ended Mar 31, 2026. Filed May 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 11, 2026

TTRX$9.92+1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · Additional Paid-in · Subscription · Accumulated · Stockholders’
Shares · Amount · Capital · Receivable · Deficit · Equity
As at December 31, 2025	29,445,183	$2,943	$28,143,873		$(1,070,000)	$(22,390,093)	$4,686,723
Issuance of common stock under Avenue Capital Agreement	342,857	34	1,050,933				1,050,967
Cash receipt from stock subscription receivable	-	-	-		1,070,000	-	1,070,000
Stock-based compensation expense	-	-	280,830		-	-	280,830
Net loss	-	-	-		-	(970,972)	(970,972)
As at March 31, 2026	29,788,040	$2,977	$29,475,636	$	-	$(23,361,065)	$6,117,548

Common Stock · Additional Paid-in · Subscription · Accumulated · Stockholders’
Shares* · Amount* · Capital* · Receivable · Deficit · Equity
As at December 31, 2024	26,845,690	$2,684	$19,015,897	$	-	$(19,196,013)	$(177,432)
Issuance of Stock, net of issuance costs - Reg-CF	215,972	22	777,770				777,792
Issuance of Stock, net of issuance costs - Reg-D	139,436	14	220,286		-	-	220,300
Issuance of Stock in lieu of advisory fees	54,466	5	249,995				250,000
Stock-based compensation expense	-	-	76,597		-	-	76,597
Net loss	-	-	-		-	(328,547)	(328,547)
As at March 31, 2025	27,255,564	$2,725	$20,340,545	$	-	$(19,524,560)	$818,710

*	Retroactively adjusted for 2-for-1 forward stock split.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.